Literature DB >> 35510500

Distribution of Achromobacter Species in 12 French Cystic Fibrosis Centers in 2020 by a Retrospective MALDI-TOF MS Spectrum Analysis.

Thomas Garrigos1,2, Manon Dollat1, Arnaud Magallon1,2, Anaïs Folletet1, Julien Bador1,2, Maryam Abid3, Marlène Amara4, Clémence Beauruelle5,6, Olivier Belmonte7, Pierre Boyer8,9, Emilie Cardot-Martin10, Anne-Gaëlle Cauchie4, Sylvie Colin de Verdière11, Claire Daurel12, Cécile Gaudru13,14, Farida Hamdad15, Geneviève Héry-Arnaud5,6, Baptiste Hoellinger8, Claudie Lamoureux5,6, Marie-Frédérique Lartigue3,16, Damasie Malandain12, Océane Marchand17, Caroline Piau18, Sandrine Picot19, Hélène Revillet13,14,20, Zeina Sabouni17, Catherine Neuwirth1,2, Lucie Amoureux1,2.   

Abstract

Achromobacter spp. are nonfermenting Gram-negative bacilli mainly studied among cystic fibrosis (CF) patients. The identification of the 19 species within the genus is time-consuming (nrdA-sequencing), thus data concerning the distribution of the species are limited to specific studies. Recently, we built a database using MALDI-TOF mass spectrometry (MS) (Bruker) that allows rapid and accurate species identification and detection of the multiresistant epidemic clones: A. xylosoxidans ST137 spreading among CF patients in various French and Belgium centers, and A. ruhlandii DES in Denmark. Here, we first assessed whether species identification could be achieved with our database solely by analysis of MS spectra without availability of isolates. Then, we conducted a multicentric study describing the distribution of Achromobacter species and of the clone ST137 among French CF centers. We collected and analyzed with our local database the spectra of Achromobacter isolates from 193 patients (528 samples) from 12 centers during 2020. In total, our approach enabled to conclude for 502/528 samples (95.1%), corresponding to 181 patients. Eleven species were detected, only five being involved in chronic colonization, A. xylosoxidans (86.4%), A. insuavis (9.1%), A. mucicolens (2.3%), A. marplatensis (1.1%) and A. genogroup 3 (1.1%). This study confirmed the high prevalence of A. xylosoxidans in chronic colonizations and the circulation of the clone A. xylosoxidans ST137 in France: four patients in two centers. The present study is the first to report the distribution of Achromobacter species from CF patients samples using retrospective MALDI-TOF/MS data. This easy approach could enable future large-scale epidemiological studies.

Entities:  

Keywords:  Achromobacter; DES; Maldi-TOF; ST137; cystic fibrosis; epidemiology; identification; mass spectrometry

Mesh:

Year:  2022        PMID: 35510500      PMCID: PMC9199411          DOI: 10.1128/jcm.02422-21

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   11.677


  24 in total

1.  Achromobacter veterisilvae sp. nov., from a mixed hydrogen-oxidizing bacteria enrichment reactor for microbial protein production.

Authors:  Charles Dumolin; Charlotte Peeters; Elham Ehsani; Guillaume Tahon; Evelien De Canck; Margo Cnockaert; Nico Boon; Peter Vandamme
Journal:  Int J Syst Evol Microbiol       Date:  2020-01       Impact factor: 2.747

2.  Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Authors:  B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

3.  Diversity of Achromobacter species recovered from patients with cystic fibrosis, in Argentina.

Authors:  Mariana Papalia; Carla Steffanowski; Germán Traglia; Marisa Almuzara; Pablo Martina; Laura Galanternik; Carlos Vay; Gabriel Gutkind; María Soledad Ramírez; Marcela Radice
Journal:  Rev Argent Microbiol       Date:  2019-06-26       Impact factor: 1.852

4.  Development of a database for the rapid and accurate routine identification of Achromobacter species by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS).

Authors:  T Garrigos; C Neuwirth; A Chapuis; J Bador; L Amoureux
Journal:  Clin Microbiol Infect       Date:  2020-04-10       Impact factor: 8.067

5.  Structured surveillance of Achromobacter, Pandoraea and Ralstonia species from patients in England with cystic fibrosis.

Authors:  Amy Coward; Dervla T D Kenna; Neil Woodford; Jane F Turton
Journal:  J Cyst Fibros       Date:  2019-12-18       Impact factor: 5.482

6.  Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis.

Authors:  R H V Pereira; R S Leão; A P Carvalho-Assef; R M Albano; E R A Rodrigues; M C Firmida; T W Folescu; M C Plotkowski; V G Bernardo; E A Marques
Journal:  Epidemiol Infect       Date:  2016-11-22       Impact factor: 4.434

7.  Uncovering Differences in Virulence Markers Associated with Achromobacter Species of CF and Non-CF Origin.

Authors:  Brankica Filipic; Milka Malesevic; Zorica Vasiljevic; Jovanka Lukic; Katarina Novovic; Milan Kojic; Branko Jovcic
Journal:  Front Cell Infect Microbiol       Date:  2017-05-29       Impact factor: 5.293

8.  Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Rapid Detection of Isolates Belonging to the Epidemic Clones Achromobacter xylosoxidans ST137 and Achromobacter ruhlandii DES from Cystic Fibrosis Patients.

Authors:  Thomas Garrigos; Manon Dollat; Arnaud Magallon; Angélique Chapuis; Véronique Varin; Julien Bador; Nadia Makki; Lise Cremet; Elise Persyn; Emilie Cardot-Martin; Fedoua Echahidi; Charlotte Peeters; Denis Pierard; Peter Vandamme; Alexia Verroken; Catherine Neuwirth; Lucie Amoureux
Journal:  J Clin Microbiol       Date:  2021-08-04       Impact factor: 5.948

Review 9.  Epidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature.

Authors:  Piet Cools; Erwin Ho; Katleen Vranckx; Petra Schelstraete; Bettina Wurth; Hilde Franckx; Greet Ieven; Leen Van Simaey; Sabine Van Daele; Stijn Verhulst; Frans De Baets; Mario Vaneechoutte
Journal:  BMC Microbiol       Date:  2016-06-24       Impact factor: 3.605

10.  Genomic characterization of Achromobacter species isolates from chronic and occasional lung infection in cystic fibrosis patients.

Authors:  Laura Veschetti; Angela Sandri; Cristina Patuzzo; Paola Melotti; Giovanni Malerba; Maria M Lleo
Journal:  Microb Genom       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.